Editorial: Biomarkers of PD progression: Is CSF the answer?

Neurology

Volumn 75, Issue 12, 2010, Pages 1036-1037

  Aarsland, Dag ^a   Ravina, Bernard ^b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; RIVASTIGMINE; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEMENTIA; DEMOGRAPHY; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; GAIT DISORDER; HEALTH CARE COST; HUMAN; MILD COGNITIVE IMPAIRMENT; MOOD DISORDER; NERVE DEGENERATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RATING SCALE; RISK ASSESSMENT; DISEASE COURSE; NOTE;

AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; PEPTIDE FRAGMENTS;

EID: 77957241703     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f6f272     Document Type: Editorial

References (10)

1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707. (Pubitemid 47597592)
2. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid/3 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
3. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomar-kers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-393.
4. Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129: 1177-1187.
5. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
6. Alves G, Brønnick K, Aarsland D, et al. CSF Amyloid-ajS and tau proteins, and cognitive performance in early and untreated Parkinson's disease: The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry Epub 2010 Jun 14.
7. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74:77-84.
8. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-325.
9. Ballard C, Jones EL, Londos E, Minthon L, Francis P, Aarsland D. a-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. Int Psychogeriatr 2010;22:321-327.
10. Tsigelny IF, Crews L, Desplats P, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One 2008;3:e3135.